BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 11.83 (+0.76), CMRX: 36.80 (+0.70), HEB: 0.22 (-0.02), SRPT: 13.88 (+0.47), TKMR: 13.97 (+0.14), ABIO: 0.93 (+0.04)
Arca continues Orphan Drug-stoked up move
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 10:21AM CST
ABIO: 0.93 (+0.04)
Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site
Business Wire - Thu Dec 11, 7:30AM CST
--Approximately 60 Trial Sites Planned in the United States and Canada
ABIO: 0.93 (+0.04)
Arca TF inhibitor an Orphan Drug for hemorrhagic fever
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 9:14AM CST
ABIO: 0.93 (+0.04)
ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola
Business Wire - Wed Dec 10, 7:30AM CST
--rNAPc2 Previously Tested in Over 700 Human Patients in Nine Phase 1 and 2 Cardiovascular Disease Clinical Trials
ABIO: 0.93 (+0.04)
ARCA's CFO leaving; COO appointed
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 5:11PM CST
ABIO: 0.93 (+0.04)
ARCA biopharma Announces Management Transitions
Business Wire - Mon Dec 01, 4:00PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions.
ABIO: 0.93 (+0.04)
LabCorp/ARCA biopharma GENETIC-AF Poster Presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America
Business Wire - Tue Sep 16, 7:01AM CDT
ARCA biopharma, Inc. (ARCA) (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) and ARCA personalized medicine abstract was presented yesterday evening at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.
LH: 107.69 (+0.56), ABIO: 0.93 (+0.04)
LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America
Business Wire - Mon Sep 08, 7:30AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) and ARCA personalized medicine abstract has been accepted for moderated poster presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.
LH: 107.69 (+0.56), ABIO: 0.93 (+0.04)
ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application
Business Wire - Mon Aug 18, 7:30AM CDT
--Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ABIO: 0.93 (+0.04)
LIN Media LLC Announces Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Feb 06, 6:30AM CST
LIN Media LLC ("LIN Media" or the "Company"; NYSE: LIN), a local multimedia company, today reported results for its fourth quarter and full year ended December 31, 2013.
LIN: 25.00 (-0.65), ABIO: 0.93 (+0.04)